Related Experiment Video
Updated: Jul 22, 2025
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
8.7K
Molecular predictors for decitabine efficacy in meningiomas - a pilot study
Dorothee C Spille1, Christian Thomas2, Andrea Wagner2
1Department of Neurosurgery, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, North Rhine-Westphalia, Germany.
Journal of Neuro-Oncology
|July 21, 2023
Summary
Decitabine (DCT) shows efficacy in 62% of meningioma cell lines, with early responses linked to DNMT1 expression. Further research is needed to identify predictors for sustained DCT treatment effectiveness in meningiomas.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Meningiomas lack effective chemotherapies.
- Decitabine (DCT), a DNA methyltransferase (DNMT) inhibitor, shows preclinical promise in a subset of meningiomas.
Purpose of the Study:
- To investigate the efficacy of decitabine (DCT) in treating meningioma cells.
- To identify molecular predictors for DCT response in meningiomas.
Main Methods:
- Primary meningioma cells were treated with DCT.
- Proliferation and viability were assessed using immunofluorescence and MTT assays.
- Gene expression (Ki67, DNMT1, oncogenes) and DNA methylation were analyzed.
Main Results:
- DCT (10µM) was effective in 62% of meningioma cell lines at 48 hours.
- DNMT1 expression reduction was significantly lower in DCT-resistant cells.
- Efficacy decreased to 25% by 72 hours, with no correlation to clinical or molecular factors.
Conclusions:
- Early DCT efficacy in meningiomas correlates with DNMT1 expression.
- Clinical and molecular predictors for sustained response are limited.
- Drug kinetics suggest potential benefit from repeated DCT administration.
